ABIVAX (EPA:ABVX) | WebDisclosure

Basculer en Français

8295	Companies
114850	Keywords
55292	Articles
62440	Press releases

Home
Companies
ABIVAX

BRIEF

published on 11/19/2024 at 22:35, 1 day 13 hours ago

Abivax Launches ATM Program on Nasdaq

Common Shares Biotechnology Funding Nasdaq ATM Program
BRIEF

published on 11/19/2024 at 22:35, 1 day 13 hours ago

Abivax lance un programme ATM sur le Nasdaq

Biotechnologie Financement Nasdaq Actions Ordinaires Programme ATM
PRESS RELEASE

published on 11/19/2024 at 22:30, 1 day 13 hours ago

Abivax met en place un programme « At-the-Market (ATM) » sur le Nasdaq
Abivax met en place un programme 'At-the-Market (ATM)' sur le Nasdaq pour émettre et vendre des actions ordinaires pour financer ses programmes cliniques et besoins généraux

Biotechnologie Abivax Nasdaq Programme ATM At-the-Market
PRESS RELEASE

published on 11/19/2024 at 22:30, 1 day 13 hours ago

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
Abivax establishes an At-the-Market (ATM) Program on Nasdaq, allowing issuance and sale of ordinary shares to raise up to $150 million. Implementation involves Piper Sandler & Co. as sales agent

Ordinary Shares Abivax Nasdaq ATM Program Piper Sandler
PRESS RELEASE

published on 11/19/2024 at 22:30, 1 day 13 hours ago

Abivax met en place un programme « At-the-Market (ATM) » sur le Nasdaq
Abivax met en place un programme 'At-the-Market (ATM)' sur le Nasdaq pour émettre des actions ordinaires, offrant jusqu'à 150M$, grâce à un contrat avec Piper Sandler, pour financer ses programmes cliniques

Abivax Nasdaq Émission D'actions Programme ATM Piper Sandler
BRIEF

published on 11/14/2024 at 22:06, 6 days 13 hours ago

Abivax publie ses résultats financiers du troisième trimestre 2024

Résultats Financiers Biotechnologie Abivax Rectocolite Hémorragique 3e Trimestre 2024
BRIEF

published on 11/14/2024 at 22:06, 6 days 13 hours ago

Abivax Releases Q3 2024 Financial Results

Financial Results Biotechnology Abivax Ulcerative Colitis Q3 2024
PRESS RELEASE

published on 11/14/2024 at 22:01, 6 days 13 hours ago

Abivax présente les principales informations financières du troisième trimestre 2024
Abivax présente les principales informations financières du troisième trimestre 2024, avec une trésorerie de 180,5 millions d'euros et une dette restante de 106,3 millions d'euros. La Société prévoit de financer ses activités jusqu'au quatrième trimestre 2025

Abivax Information Financière Trésorerie Trimestre 2024 Dette Restante
PRESS RELEASE

published on 11/14/2024 at 22:01, 6 days 13 hours ago

Abivax presents third quarter 2024 key financial information
Abivax presents key financial information for the third quarter of 2024. The company announced updates on operational goals and debt status. Details on Abivax's cash and principal debt outstanding are provided

Financial Information Abivax Quarter Results Clinical-stage Biotechnology Debt Status
PRESS RELEASE

published on 11/14/2024 at 22:01, 6 days 13 hours ago

Abivax présente les principales informations financières du troisième trimestre 2024
Abivax présente les informations financières du troisième trimestre 2024, avec une trésorerie de 180,5 millions d'euros et une dette de 106,3 millions d'euros. Détails ici

Abivax Dette Trésorerie Informations Financières Troisième Trimestre

Accesswire

Published on 11/21/2024 at 11:30, 12 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 1 hour 39 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 1 hour 42 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 2 hours 42 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 11 hours 7 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 11:30, 12 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 41 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 42 minutes ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 46 minutes ago

ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 1 hour 12 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024

Les Echos

Published on 11/21/2024 at 06:58, 4 hours 44 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 44 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 44 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 35 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 22 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE